cvxga
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05736835)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06742281 | Phase 2 | Dec 5, 2024 | CyanVac LLC, Department of Health and Human Services |
| NCT05736835 | Phase 2 | Jun 30, 2023 | CyanVac LLC, Good Samaritan Hospital, Cincinnati |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CyanVac LLC | For profit | 2 | 2 | 1 | 2023 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2024 |
| Good Samaritan Hospital, Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1